Urogen Pharma (NASDAQ:URGN – Free Report) – Investment analysts at HC Wainwright upped their Q3 2027 earnings estimates for Urogen Pharma in a research note issued to investors on Thursday, August 6th. Finally, UBS Group reiterated a “buy” rating on shares of Urogen Pharma in a research report on Thursday, July 9th. Urogen Pharma Stock Down 1.8%Shares of NASDAQ URGN opened at $45.60 on Friday. Urogen Pharma News SummaryHere are the key news stories impacting Urogen Pharma this week:Positive Sentiment: HC Wainwright raised its price target to $75 from $45 and reiterated a Buy rating. Featured ArticlesReceive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.